Tag Archives: immunology

January, 2018

18 January
Sandoz Announces Exclusive Global Collaboration with Biocon on Next-Generation Biosimilars

Holzkirchen, 18 January 2018 – Sandoz, a Novartis division and the global leader in biosimilars, today announced a global partnership with Asia’s premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide. Under the terms of the agreement, both companies will share responsibility …
Share

4 October
Celgene and Nimbus Enter Immunology Alliance to Develop Programs for Autoimmune Disorders

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, announced today the initiation of a long-term strategic alliance with Celgene Corporation (NASDAQ: CELG) in immunology. Under the terms of the agreement, Celgene will receive an option to acquire each program in the alliance …
Share

22 September
Provention Bio Enters Licensing Agreement with Janssen for Two Mid-Stage GI Immunology Candidates

LEBANON, N.J., Sept. 21, 2017 /PRNewswire/ — Provention Bio, Inc., a clinical stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated diseases, announced today that it has entered into agreements with Janssen Pharmaceutica NV and Janssen Sciences Ireland UC [Janssen] to in-license …
Share

9 January
Amgen and Immatics Partner To Develop Novel Bispecific Cancer Immunotherapies

THOUSAND OAKS, Calif. and TUEBINGEN, Germany, Jan. 9, 2017 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Immatics Biotechnologies GmbH, a leading company in the field of cancer immunotherapy, today announced a research collaboration and exclusive license agreement to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers. The collaboration will combine Immatics’ world-leading …
Share

7 March
AbbVie Pays $595 Million for Rights to Boehringer Ingelheim’s Psoriasis Drug

NORTH CHICAGO, Ill. & INGELHEIM, Germany–(BUSINESS WIRE)–AbbVie (NYSE:ABBV) and Boehringer Ingelheim today announced a global collaboration to develop and commercialize BI 655066, an anti-IL-23 monoclonal biologic antibody in Phase 3 development for psoriasis. AbbVie and Boehringer Ingelheim also are evaluating the potential of this biologic therapy in Crohn’s disease, psoriatic …
Share

7 December
Morphotek Announces Early-Stage Results from its Rheumatoid Arthritis Study

EXTON, Pa., Dec. 7, 2015 /PRNewswire/ — Morphotek®, Inc., a subsidiary of Eisai Inc., announced today results from Study MORAb-022-001, a single-dose, dose-ascending, placebo-controlled, Phase 1 trial evaluating the safety and tolerability of its investigational, anti-GM-CSF, monoclonal antibody, MORAb-022 in healthy subjects (n=26) and mild-to-moderate Rheumatoid Arthritis (RA) patients (n=25). In this …
Share

1 June
Baxter, Mayo Clinic and VPD Form Vitesse Biologics to Accelerate Drug Development

In an effort to accelerate therapeutic innovation, Baxter Ventures, the Mayo Clinic and Velocity Pharmaceutical Development (VPD) have teamed up to form a new company called Vitesse Biologics, LLC. The formation of Vitesse is a unique collaboration model initiated by Baxter Ventures to focus on the development of antibody and …
Share